Today, there are an increasing number of targeted, systemic therapies available to treat moderate to severe atopic dermatitis (AD), thanks to a greater understanding of the pathophysiology of this disease. In this one-hour activity, you’ll learn about these treatment advances in AD and how to apply them in your own practice through shared decision making with your patients. Led by three thought leaders in AD care, “Clearing the Way” takes you through four educational modules that cover the evolving clinical practice guidelines, present and future systemic therapies, assessing the impact of AD and treatment outcomes, and collaborative care and decision making. Stay up to date on innovative therapies that can help clear the way for your patients with AD!

Target Audience:

The primary target audiences for this activity are dermatologists, nurse practitioners, and physician assistant dermatology providers. Allergists, immunologists, primary care providers, pharmacists, and other healthcare professionals who are involved in AD care and are interested in advances in the development of new therapies for AD can also benefit from participation in this education.

Learning Objectives:

As a result of participation in this educational activity, learners should increase their ability to:

1. Translate the evidence about efficacy and safety of targeted systemic therapies for AD into clinically meaningful information for AD care.
2. Apply evolving recommendations for treatment and management of moderate to severe AD.
3. Incorporate disease severity evaluation, patient-reported outcomes (PRO) measures, and quality of life (QoL) scores into the assessment of the impact of AD disease and treatments in routine clinical practice.
4. Engage patients and caregivers in shared decision making about treatment goals and options for AD.

Faculty:

Linda Stein Gold is Director of Dermatology Clinical Research for the Henry Ford Health System in Detroit, Michigan. She is also Division Head of Dermatology for the Henry Ford Health System in West Bloomfield, Michigan. She received her medical degree from University of Pennsylvania School of Medicine in Philadelphia, completed an internship in the Department of Internal Medicine at the Hospital of the University of Pennsylvania in Philadelphia, and was Chief Resident in the Department of Dermatology at Henry Ford Hospital in Detroit.

Dr. Stein Gold is the incoming Vice President of the American Academy of Dermatology. She has completed her service on the Board of Directors of the American Academy of Dermatology and the Executive, Priorities, Corporate Relations, and Budget Committees. She has authored more than 200 articles published in journals including The New England Journal of Medicine and Journal of the American Academy of Dermatology.

Dr. Stein Gold is a frequent national and international lecturer on the areas of psoriasis, atopic dermatitis, and fungal infections. Her recent research has focused on treatments for papulopustular rosacea, acne vulgaris, plaque-type psoriasis, atopic dermatitis, and alopecia areata.

Neil J. Korman, MD, PhD, is a Professor of Dermatology at Case Western Reserve University in Cleveland, Ohio. He is also a Distinguished Physician of University Hospitals Cleveland Medical Center (UHCMC) and is the Director of the Dermatology Clinical Trials Unit in the Department of Dermatology at UHCMC. In addition, he serves as the Clinical Director of the Murdough Family Center for Psoriasis, a comprehensive psoriasis research, education, and treatment program. Dr. Korman earned his medical degree (1984) and PhD in biomedical engineering (1982) at Case Western Reserve University. His postdoctoral training included a medical internship and dermatology residency at UHCMC and an immunodermatology fellowship at the Dermatology Branch of the National Institutes of Health in Bethesda, Maryland.

Dr. Korman is board certified in Dermatology and holds subspecialty board certification in Dermatological Immunology/Diagnostic and Laboratory Immunology. He is also a member of the American Dermatological Association.

Dr. Korman has published over 200 articles in the peer-reviewed literature. He has been the principal or co-principal investigator in more than 100 clinical trials, the majority were focused on psoriasis, including trials of all of the major biologic agents approved for psoriasis and he has also been involved in several translational mechanism of action studies in psoriasis.

Ms. Lakshi Aldredge is an Adult Nurse Practitioner (NP) who practices at the VA Portland Healthcare System in the Dermatology Service and is also the Director for the Primary Care NP Residency Program. She obtained her Master of Science in Nursing Degree from the University of Portland in 1998 as well as national certification as an Adult Nurse Practitioner that same year. She obtained her Dermatology Nurse Practitioner Certification in 2018. She is Past Chair of the Nurse Practitioner Society of the Dermatology Nurses’ Association (DNA), Past President of the DNA and past Co-chair of the Dermatology Specialty Practice Group of the American Academy of Nurse Practitioners. She currently serves as the President of the Society of Dermatology Nurse Practitioners. She is a member of the National Psoriasis Foundation Emeritus Medical Advisory Board and served on the Editorial Board for the Journal of the Dermatology Nurses’ Association and is Associate Editor for Journal of Psoriasis and Psoriatic Arthritis. She has a special interest in psoriasis, as well as in educating health care providers about the role of NPs in the field of dermatology. Ms. Aldredge has published numerous articles on the management of patients with psoriatic disease. She received the VA’s Nursing Excellence Award in 2008 and the President’s Award from the DNA in 2015. She also received the 2016-17 Outstanding Allied Health Award from the National Psoriasis Foundation. In March 2021, she was selected as a Fellow of the American Association of Nurse Practitioners.

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

•The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, Megan Ragan
Planners and Reviewers (AKH Inc.): Dorothy Caputo, MA, BSN, RN, Bernadette Makar, MSN, APRN-BC, NP-C, Dorothy A. Duffy, RPh

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Presenter: Linda Stein Gold, MD
Advisor: AbbVie, Arcutis Biotherapeutics, Dermavant Sciences, Inc., Eli Lilly and Company, Incyte Corporation, Leo Pharma, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi S.A.

Consultant: AbbVie, Arcutis Biotherapeutics, Dermavant Sciences, Inc., Eli Lilly and Company, Incyte Corporation, Leo Pharma, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi S.A.

Researcher: AbbVie, Arcutis Biotherapeutics, Dermavant Sciences, Inc., Eli Lilly and Company, Incyte Corporation, Leo Pharma, Pfizer Inc.

Speaker: AbbVie, Dermavant Sciences, Inc., Incyte Corporation, Leo Pharma, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi S.A.

Presenter: Neil J. Korman, MD, PhD
Independent contractor (including contracted research): AbbVie, Amgen Inc., Argenx,Bristol Myers Squibb Company, Castle Biosciences, Inc., Celgene Corporation, ChemoCentryx, Dermira, Inc., Eli Lilly and Company, Galderma S.A., Kyowa Kirin Co., Ltd., LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Principia Biopharma Inc., Regeneron Pharmaceuticals, Rhizen Pharmaceuticals AG, Sun Pharmaceutical Industries Ltd., Union Chimique Belge (UCB), VYNE Therapeutics, XBiotech USA, Inc.

Consultant: AstraZeneca plc, Novartis AG

Advisor: AbbVie, Argenx, Bausch Health Companies Inc., Boehringer Ingelheim, Bristol Myers Squibb Company, Dermavant Sciences Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Leo Pharma, Novartis AG, Pfizer Inc., Principia Biopharma Inc., Regeneron Pharmaceuticals, Sanofi S.A., Sun Pharmaceutical Industries Ltd., UCB

Speaker: AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi S.A.

Presenter: Lakshi M. Aldredge, MSN, ANP-BC, DCNP, FAANP
Consultant: AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb Company, Dermavant Sciences Inc., Eli Lilly and Company, Incyte, Janssen Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Union Chimique Belge (UCB)

Advisor: AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb Company, Dermavant Sciences Inc., Eli Lilly and Company, Incyte, Janssen Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., UCB

Speaker: AbbVie, Janssen Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., UCB

CME Content Review:

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and AbbVie.

The content of this activity was independently reviewed by two peer reviewers and one patient reviewer. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.0 contact hour.

Nurse Practitioners

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1.0 contact hour (which includes 1.0 hour(s) of pharmacology).

This activity is supported by an educational grant from AbbVie.